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http://dx.doi.org/10.1016/j.stemcr.2016.07.001SUMMARYWhile Cas9 nucleases permit rapid and efficient generation of gene-edited cell lines, the CRISPR-Cas9 system can introduce undesirable
‘‘on-target’’ mutations within the second allele of successfullymodified cells via non-homologous end joining (NHEJ). To address this, we
fused the Streptococcus pyogenesCas9 (SpCas9) nuclease to a peptide derived from the humanGeminin protein (SpCas9-Gem) to facilitate
its degradation during theG1 phase of the cell cycle, whenDNA repair byNHEJ predominates.We also usemRNA transfection to facilitate
low and transient expression of modified and unmodified versions of Cas9. Although the frequency of homologous recombination was
similar for SpCas9-Gem and SpCas9, we observed amarked reduction in the capacity for SpCas9-Gem to induce NHEJ-mediated indels at
the target locus. Moreover, in contrast to native SpCas9, we demonstrate that transient SpCas9-Gem expression enables reliable gener-
ation of both knockin reporter cell lines and genetically repaired patient-specific induced pluripotent stem cell lines free of unwanted
mutations at the targeted locus.INTRODUCTION
The utility of human pluripotent stem cells (hPSCs) is
significantly enhanced by an ability to precisely modify a
chosen locus with minimal impact on the remaining
genome. Ideally this is achieved by gene targeting, which
historically has proved challenging in hPSCs due to the
low frequency of homologous recombination (HR) (Zwaka
and Thomson, 2003). More recently, genetic modification
of hPSCs has been facilitated through the use of nucleases
to induce DNA double-strand breaks (DSBs) at a target
locus, which are subsequently repaired by HR or the er-
ror-prone non-homologous end-joining (NHEJ) pathway.
Zinc finger nucleases and transcription activator-like endo-
nucleases (TALENs) were the first sequence-specific nucle-
ases employed for gene targeting in hPSCs (Hockemeyer
et al., 2009, 2011; Zou et al., 2009). However, both ap-
proaches require the design, expression, and validation of
a new pair of proteins for every targeted locus, rendering
both of these platforms time consuming and labor inten-
sive. Due to its simplicity, ease of manipulation, and high
efficiency, the clustered regularly interspaced short palin-
dromic repeats (CRISPR)-Cas9 system is fast becoming the
preferredmethod for the precisemodification of eukaryotic
genomes (Cho et al., 2013; Cong et al., 2013; Jinek et al.,
2012, 2013; Mali et al., 2013). However, a potential limita-
tion to this system is the introduction of ‘‘on-target’’
disruptive mutations caused by Cas9-induced NHEJ occur-
ring within the untargeted allele of knockin or gene-cor-508 Stem Cell Reports j Vol. 7 j 508–517 j September 13, 2016 j ª 2016 The
This is an open access article under the CC BY-NC-ND license (http://creativrected hPSC clones (Howden et al., 2015; Merkle et al.,
2015). Although reducing the Cas9 dosage may limit
both off-target and on-target NHEJ activity (Cradick et al.,
2013), a corresponding decrease in gene-targeting effi-
ciency is also expected.
Previous studies, including one in normal human fibro-
blasts, have demonstrated that HR activity is virtually ab-
sent during G1 phase, increases sharply in S phase, and be-
gins to decrease by G2/M, whereas NHEJ activity occurs
throughout the cell cycle (Mao et al., 2008; Saleh-Gohari
and Helleday, 2004). Hence, controlling the presence of
Cas9 protein during specific stages of the cell cycle could
minimize the formation of undesirable insertion or dele-
tionmutations (indels) induced byNHEJ.Wehypothesized
that the presence of Cas9 in G1 would induce DNA DSBs
that would invariably be repaired by error-prone NHEJ,
whereas elimination of the nuclease within this phase
could potentially limit the introduction of disruptive in-
dels at the target locus.
Previous studies have shown that fusion of fluorescent
reporters to anN-terminal peptide derived from the human
Geminin protein resulted in their proteolytic destruction
in the late M and G1 phases of the cell cycle (Pauklin and
Vallier, 2013; Sakaue-Sawano et al., 2008), a process medi-
ated by the APCCdh1 E3 ligase complex (Nishitani et al.,
2004). In this study, an identical Geminin-derived peptide
was fused to SpCas9 (designated SpCas9-Gem) to facilitate
nuclease degradation during G1. We show that the fre-
quency of HR is not impaired by fusion of the GemininAuthor(s).
ecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Analysis of SpCas9-Gem Protein
(A) Schematic diagram of the Cas9 variants generated in this study. Unmodified SpCas9, and the SpCas-Gem and SpCas9-Cdt1 variants were
cloned downstream of a T7 promoter to permit their in vitro transcription. NLS, nuclear localization signal.
(B) Flow cytometric analysis following intracellular staining of Cas9 protein in H9 cells transfected with mRNA encoding SpCas9, SpCas9-
Gem, or SpCas9-Cdt1. Cells were analyzed at 6 hr and 18 hr post transfection and incubated in the presence of Hoechst 33342 prior to
harvesting. Untransfected H9 cells are shown as a negative control.
(C) Western blot analysis of Cas9 protein expression 12 hr post transfection of SpCas9, SpCas9-Gem, or SpCas9-Cdt1 in H9 cells. Prior to
harvesting, cells were incubated in the presence of Hoechst 33342 and the G0/G1 and S/G2 subpopulations were sorted based on DNA
content. Anti-actin was included as a loading control.peptide to SpCas9, but observe a significant decrease in
NHEJ frequency, as evidenced by the absence of indels
within the target locus. Together, these features of
SpCas9-Gem permit efficient and reliable generation of
both knockin cell lines and gene-corrected patient-specific
induced pluripotent stem cell (iPSC) lines that are free of
disruptive mutations within the untargeted allele.RESULTS
SpCas9-Gem mRNA Transfection Results in Transient
and Cell-Cycle-Dependent Protein Expression
SpCas9-Gem was generated by fusing the first 110 amino
acids of Geminin to the C-terminal region of SpCas9,
following removal of the C-terminal nuclear localization
signal (Figure 1A). Because levels of Geminin and Cdt1
oscillate inversely, whereby Cdt1 levels are highest during
G1 and Geminin levels are highest during the S and G2
phases (Nishitani et al., 2004; Sakaue-Sawano et al.,
2008), we also generated a second variant of SpCas9
(termed SpCas9-Cdt1) by fusing SpCas9 to amino acids30–120 of Cdt1. Fusion of this peptide to fluorescent re-
porters has previously been shown to be sufficient for
marking cells in G1 (Pauklin and Vallier, 2013; Sakaue-Sa-
wano et al., 2008). An upstream T7 promoter was used
for in vitro transcription of mRNA encoding SpCas9,
SpCas9-Gem and SpCas9-Cdt1 (Figure 1A). We performed
intracellular staining and flow cytometric analysis
following transfection of mRNA encoding each of the
Cas9 variants in the human embryonic stem cell line, H9,
to examine their abundance and stability over time. Prior
to analysis, cells were incubated in the presence of Hoechst
33342 to distinguish cells in G0/G1 and S/G2 phases of the
cell cycle. Although at 6 hr post transfection all three Cas9
variants were present at similar levels, by 18 hr post trans-
fection a marked reduction in both SpCas9-Gem and
SpCas9-Cdt1 abundance was observed relative to native
SpCas9 (Figure 1B). Furthermore, at both time points
SpCas9-Gem appeared to be expressed at higher levels in
the S/G2 subpopulation, which was not observed for the
native SpCas9 or SpCas9-Cdt1 variant. Although signifi-
cant expression of SpCas9-Gem in the G0/G1 subpopula-
tion was also noted, we hypothesized that this could beStem Cell Reports j Vol. 7 j 508–517 j September 13, 2016 509
due to the binding of CRISPR-Cas9 antibody to not just the
intact Cas9 protein but also fragmented protein that was
undergoing or had recently undergone proteolytic destruc-
tion. To address this concern we performed western blot
analysis on the G0/G1 and S/G2 subpopulations 12 hr after
the introduction of mRNA encoding each of the Cas9
variants into H9 cells, which were subsequently sorted by
fluorescence-activated cell sorting based on DNA content.
Using this analysis we clearly detected higher SpCas9-
Gem protein levels in the S/G2 population relative to
the G0/G1 (Figure 1C), confirming cell-cycle-dependent
expression of the SpCas9-Gem variant.
Generation of Indel-Free Knockin Reporter iPSCs from
Human Fibroblasts
To evaluate the HR and NHEJ activities associated with
SpCas9-Gem and SpCas9-Cdt1, we used a recently des-
cribed method that permits both rapid and efficient gener-
ation of gene-edited induced pluripotent stem cell (iPSC)
lines following a single electroporation of human fibro-
blasts (Howden et al., 2015). As in the previous study, we
chose to target the DNMT3B gene with an EGFP reporter
(Figure 2A), since DNMT3B is highly expressed in pluripo-
tent cells and quickly downregulated following differentia-
tion, allowing targeted iPSC colonies to be easily identified
by fluorescent microscopy (Figure 2B) and flow cytometry
(Figure 2C). Episomal reprogramming vectors, a plasmid
encoding a single-guide RNA (sgRNA) specific to sequence
spanning theDNMT3B start codon and a plasmid encoding
an EGFP reporter flanked by 1.1 kb and 0.7 kb and homol-
ogy arms specific to sequences upstream and downstream
of theDNMT3B start codon (Figure 2A) were co-transfected
with mRNA encoding SpCas9, SpCas9-Gem, or SpCas9-
Cdt1. No observable difference in cell viability was associ-
ated with transfection of mRNA encoding SpCas9-Gem or
SpCas9-Cdt1 compared with the native SpCas9 (Fig-
ure S1A). To estimate targeting efficiency associated with
each of the Cas9 variants, we passaged cells approximately
3 weeks post transfection using EDTA to selectively remove
residual fibroblasts from iPSCs (Howden et al., 2015). After
three passages the total cell population was analyzed by
flow cytometry. As measured by the number of EGFP-ex-
pressing cells, targeting efficiency was comparable for
both the SpCas9 and SpCas9-Gem variants (17.1% versus
16.5%) but slightly lower for the SpCas9-Cdt1 variant
(9.9%) (Figure 2C). We did not observe any EGFP-express-
ing cells when Cas9 mRNA was omitted from the transfec-
tion (data not shown). At 2–3 weeks post transfection,
randomly selected EGFP-expressing and EGFP non-ex-
pressing (EGFPneg) colonies were picked and expanded for
further analysis (Figure 2B and Table 1). EGFP-expressing
clones were further categorized as either having a single
allele (EGFP+) or both DNMT3B alleles (EGFP++) targeted,510 Stem Cell Reports j Vol. 7 j 508–517 j September 13, 2016based on flow cytometry and PCR analysis (Figures 2D
and S1). Of 28 EGFP-expressing clones isolated from trans-
fections performedwith SpCas9 or SpCas9-GemmRNA, we
observed 11 (39%) and 6 (21%) EGFP++ clones, respectively
(Table 1). The SpCas9-Cdt1 variant resulted in only a single
(6%) EGFP++ clone out of 17 clones analyzed. Next we
analyzed the untargeted allele of single-targeted EGFP+
clones by Sanger sequencing of the PCR product amplified
from genomic DNA using primers flanking the DNMT3B
start codon (Figure 2D). With respect to unmodified
SpCas9, NHEJ activity could be detected within the untar-
geted allele in all 17 clones analyzed (Figure 2E), as evi-
denced by the presence of indels ranging from 1 bp to
over 1 kb in size (Table S1). In contrast, of 22 clones
analyzed, we identified 8 (36%) ‘‘indel-free’’ clones derived
using the SpCas9-Gem variant, which did not contain mu-
tations within the untargeted DNMT3B allele. Interest-
ingly, indel-free clones could also be generated with the
SpCas9-Cdt1 variant, albeit with a lower efficiency (2 out
of 16 EGFP+ clones [12%] analyzed). We next investigated
the NHEJ activity associated with each of the Cas9 variants
in EGFPneg clones, again by analysis of PCR amplicons en-
compassing the DNMT3B start codon and surrounding
sequence. Sequencing analysis revealed indels in all 25
EGFPneg clones expanded and analyzed from experiments
performedwith SpCas9, with all but one clone carrying dis-
ruptions in both DNMT3B alleles (Figure 2F and Table S2).
Mutations in DNMT3B could also be found in the vast ma-
jority (95%) of EGFPneg clones isolated and expanded from
experiments performed using SpCas9-Cdt1 mRNA; how-
ever, approximately half of these had only one allele dis-
rupted by NHEJ with the other allele remaining intact.
Conversely, only 35% of EGFPneg clones generated with
the SpCas9-Gem variant containedmutations inDNMT3B,
with single allele and biallelic disruption in 13% and 22%
of EGFPneg clones, respectively.
Generation of Indel-Free Gene-Corrected iPSCs from
Patient Fibroblasts
Next we assessed the capacity of SpCas9-Gem to facilitate
the derivation of gene-corrected iPSCs lacking deleterious
indels within the second allele. To demonstrate this, we
chose to correct an autosomal dominant G > A transition
(R853Q) in exon 14 of the SCN2A gene identified in a pedi-
atric patient with severe epilepsy.We attempted to simulta-
neously reprogram and correct the disease-causing muta-
tion in the patient fibroblasts using our one-step protocol
and mRNA encoding SpCas9, SpCas9-Gem, or SpCas9-
Cdt1. To facilitate gene repair we used an sgRNA encom-
passing the patient-specific mutation and a plasmid encod-
ing wild-type SCN2A sequence, comprising z0.9-kb arms
flanking the intended DNA DSB. A silent 3-bp change
was also included to aid in identification of correctly
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Figure 2. Generation of Knockin Reporter iPSC Lines Using Cas9 Variants
(A) Schematic diagram of the DNMT3B locus and the homologous template used for gene targeting. pA, polyA signal; Ex, exon.
(B) Representative phase contrast and fluorescent images depicting an EGFP-expressing and non-expressing iPSC colony emerging
approximately 2 weeks after simultaneous reprogramming and gene targeting of DNMT3B in human fibroblasts.
(C) Targeting efficiency associated with SpCas9, SpCas9-Gem and SpCas9-Cdt1 assessed by flow cytometric analysis of the total iPSC
population after EDTA passaging, initiated approximately 3 weeks post electroporation.
(D) Schematic of the DNMT3B locus showing location of PCR primers used to screen EGFP-expressing clones, and representative gel analysis
of the PCR products amplified from EGFP-expressing clones. These primers preferentially amplify the untargeted allele in monoallelic
(EGFP+) clones, whereas only the larger 2.9-kb band is visible following PCR analysis of biallelic (EGFP++) clones.
(E) Proportion of single-targeted EGFP+ clones identified without disruption of the other untargeted DNMT3B allele.
(F) Proportion of EGFPneg (untargeted) iPSC clones with one or both DNMT3B alleles disrupted by NHEJ. EGFP+ and EGFPneg colonies were
isolated and expanded from three independent experiments, performed with each version of Cas9. Data represent mean ± SEM from three
independent experiments.modified clones and to minimize Cas9 recutting following
HR with the homologous template (Figure 3A). To assess
HR and NHEJ activities, we extracted genomic DNA from
randomly selected iPSC colonies, followed by sequencing
analysis of the PCR product amplified using primers flank-ing exon 14 of SCN2A. With respect to the SpCas9-Gem
variant, gene repair was observed in 5 of 30 clones (17%)
screened, as evidenced by the loss of the disease-causing
mutation and gain of the 3-bp synonymous change carried
by the corrective plasmid (Figures 3B and 3C). IndelStem Cell Reports j Vol. 7 j 508–517 j September 13, 2016 511
Table 1. Number of iPSC Clones Isolated, Expanded, and
Characterized Following Targeting of the DNMT3B Locus
Targeted (EGFP+) Clones Non-targeted
(EGFPneg)
Clones
Total Clones
AnalyzedOne Allele Both Alleles
SpCas9 17 (0) 11 25 53
SpCas9-Gem 22 (8) 6 23 51
SpCas9-Cdt1 16 (2) 1 22 39
The number of clones with EGFP targeted to one allele without an additional
mutation in the untargeted allele is shown in parentheses.formation at the second SCN2A allele could not be detected
in four of the gene-corrected clones, although biallelic HR
with the repair template was observed, as evidenced by ho-
mozygosity for the plasmid-specific 3-bp change (TCA >
AGC). Targeted correction of SCN2A was also observed
with the SpCas9 and SpCas9-Cdt1 variants, although at a
lower frequency (9.7% and 3.3%, respectively). Further-
more, only one gene-corrected clone out of 31 (3.3%)
iPSC colonies screened for both the SpCas9 and SpCas9-
Cdt1 variants did not contain a secondary mutation at
the other SCN2A allele. As seen in the previous DNMT3B
targeting experiment, sequencing analysis of uncorrected
iPSC clones revealed a much lower incidence of NHEJ asso-
ciated with the SpCas9-Gem variant compared with un-
modified SpCas9 and the SpCas9-Cdt1 variant (Figure 3D).
Although our sgRNAwas designed to recognize themutant
over wild-type SCN2A allele, indels could be detected in
both alleles for each of the Cas9 variants tested. This is
not unexpected, since single mismatches in sgRNA are
often well tolerated, even within the 30 end of the proto-
spacer sequence (Fu et al., 2013; Hsu et al., 2013). However,
analysis of all clones with only a single allele disrupted by
NHEJ did reveal a preference for the mutant allele (Fig-
ure 3D and Table S3).
SpCas9-Gem Retains HR Capacity with Reduced NHEJ
Activity in hPSCs
To evaluate the SpCas9-Gem variant in a cell type other
than human fibroblasts, we utilized iPSC lines generated
in the previous experiments (see Figure S1) that harbor
EGFP targeted to both DNMT3B alleles. For a homologous
template we used a plasmid encoding the full-length BFP
sequence that was identical to EGFP except for C > G and
T > C transitions, corresponding to two consecutive amino
acid changes (T67S and Y68H) (Figure 4A). This is sufficient
for conversion of EGFP to BFP reporter expression (Glaser
et al., 2016). We also included a plasmid encoding an
sgRNA that specifically recognizes EGFP over BFP. Using
this system in an iPSC line constitutively expressing512 Stem Cell Reports j Vol. 7 j 508–517 j September 13, 2016EGFP, we simultaneously estimated both HR (as deter-
mined by the number of BFP+ cells) and NHEJ frequencies
(as determined by the number of EGFPneg cells) in the total
population of transfected cells after 3 days by flow cytom-
etry (Figure 4B). SpCas9 or SpCas9-Gem mRNA resulted
in similar levels of HR, as determined by the number of
BFP+ cells, when co-transfected with BFP plasmid DNA
and EGFP-specific sgRNA into two independent EGFP++
iPSC lines (Figures 4B and 4C). However, a significantly
reduced proportion of EGFPneg cells, caused by disruption
of the EGFP gene, was consistently associated with the
SpCas9-Gem variant. This approximately 2-fold reduction
in NHEJ activity was observed in both the presence and
absence of the BFP donor template (Figure 4C). To deter-
mine whether simply lowering the nuclease dosage could
also achieve reduced indel formation while maintaining
HR efficiency, we co-transfected 50, 100, 250, or 500 ng
of mRNA encoding SpCas9 with the BFP plasmid and
EGFP-specific sgRNA plasmid into iPSCs constitutively ex-
pressing EGFP. In agreement with previous studies, lower
concentrations of Cas9 did indeed reduce NHEJ frequency,
although a consequential decrease inHR efficiencywas also
observed. Specifically, the lowest dose of SpCas9 mRNA
(50 ng) reduced NHEJ to rates observed with 500 ng of
the SpCas9-Gem mRNA but resulted in more than 5-fold
reduction in HR frequency (Figure S2A). A positive correla-
tion between Cas9 mRNA concentration and HR efficiency
was also observed when targeting EGFP to the DNMT3B
locus in H9 cells (Figure S2B). Furthermore, no significant
difference in targeting efficiency was observed following
co-transfection of mRNA encoding SpCas9 or SpCas9-
Gem with the DNMT3B-EGFP homologous template and
DNMT3B-specific sgRNA in H9 cells (Figure S3A). We also
evaluated the ‘‘on-target’’ indel frequency of the SpCas9-
Gem variant following targeting of the DNMT3B and
GAPDH loci in H9 cells. In these experiments, we used tar-
geting constructs that contain a drug-selectable marker to
facilitate rapid isolation, expansion, and characterization
of individual colonies (Figures S3B and S3C). Consistent
with the EGFP-to-BFP conversion assay in the previous ex-
periments, an approximately 2- to 3-fold reduction inNHEJ
activity was associated with the SpCas9-Gem variant
compared with native SpCas9.DISCUSSION
The recent development of the CRISPR-Cas9 system
will undoubtedly have an enormous impact on the utility
of hPSCs for the elucidation of developmental processes,
disease modeling, or even personalized regenerative medi-
cine. However, the reliable and efficient generation of
knockin or gene-corrected hPSCs without secondary
UAGUAAGGUC
T TGTTA TGT
u
AC C AG
cG
C
CA a
C CT ATTCC G
a
CTG taaattaactgggaggA
uu
serarg phe
CAG G
gln
arg
leuleuvalserleu
Ex 26Ex 1 Ex 14
SCN2A
A
0
4
8
12
16
0
20
40
60
80
100
B
C
9.7%
16.6%
13.3%
3.3% 3.3%
uncorrected
corrected (heterozygous)
corrected (homozygous)
corrected + indel
total indel-free
%
  g
en
e 
co
rre
ct
ed
 c
lo
ne
s 
mutant allele wt allele
both alleles total
SpCas9 SpCas9-
Gem
SpCas9-
Cdt1
SpCas9 SpCas9-
Gem
SpCas9-
Cdt1
%
   
cl
on
es
 w
ith
 in
de
l 
D
Figure 3. Generation of Gene-Corrected
iPSC Lines Using Cas9 Variants
(A) Schematic diagram of the SCN2A gene,
with mutation in exon 14. The crRNA
sequence used (red), PAM location (bold),
and the patient-specific autosomal domi-
nant mutation (blue) along with the 3-bp
synonymous change (green) incorporated
into the plasmid template used for repair are
shown. Exon sequences are in uppercase,
introns in lowercase.
(B) Sequencing analysis of exon 14 of the
SCN2A gene from a representative uncor-
rected patient-specific iPSC clone and three
gene-corrected iPSC clones with either one
allele targeted (heterozygote), both alleles
targeted (homozygote), or one allele tar-
geted and the other disrupted by NHEJ.
(C) Proportion of gene-corrected iPSC clones
without disruption of the second SCN2A
allele.
(D) Proportion of uncorrected iPSC clones
with one or both SCN2A alleles disrupted by
NHEJ.deleterious mutations has been somewhat elusive. Because
cell-cycle phase largely determines the frequency of the
alternative HR andNHEJ DNA repair pathways, it is reason-
able to expect that controlling the timing of a DNA DSB
may selectively favor one pathway over the other. Chemi-
cal-mediated cell synchronization followed by timed deliv-
ery of Cas9-guide RNA ribonucleoprotein complexes has
recently been shown to be effective for increasing HR effi-
ciency in the human cell line HEK-293, although whether
this led to decreased NHEJ activity in alleles that had not
undergone HR was not reported (Lin et al., 2014). More-
over, different cell types, such as hPSCs, have distinct re-
quirements for synchronization, which do not always
translate to effective increases in HR. Recent studies have
also shown that small molecules such as SCR7 may inhibit
NHEJ and consequently promote HR (Maruyama et al.,
2015). However, these kinds of approaches are likely tohave variable effects across different cell types and may
potentially exhibit undesirable cytotoxic effects, rendering
them unsuitable in therapeutic contexts. In an attempt to
address some of these issues, we generated a variant of
the SpCas9 nuclease (SpCas9-Gem) that persists during
stages of the cell cycle when the HR pathway is active,
but is degraded during G1, when NHEJ activity predomi-
nates. An attractive feature of the SpCas9-Gem variant is
its potential applicability to different cell types without a
requirement for cells to be manipulated or specially pre-
pared prior to introduction of the gene-editing factors. In
the current study we have demonstrated the versatility of
SpCas9-Gem in primary human fibroblasts and hPSCs,
two cell types known to exhibit very different cell-cycle
profiles. Although the lower frequency of NHEJ associated
with SpCas9-Gem was less pronounced in hPSCs, we hy-
pothesize that this may be attributed to the dramaticallyStem Cell Reports j Vol. 7 j 508–517 j September 13, 2016 513
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Figure 4. Evaluation of SpCas9-Gem in Pluripotent Stem Cells
(A) Schematic summary of EGFP-to-BFP conversion targeting strategy. The location of the two amino acid changes and the Cas9 target site
(red) are indicated.
(B and C) Representative flow cytometry plots (B) and graphical plot (C) depicting the proportion of BFP+ (targeting efficiency) and
EGFPneg cells (NHEJ frequency) assessed 3 days after the introduction of SpCas9 and SpCas9-Gem with and without a BFP homologous
template in iPSCs constitutively expressing EGFP. Data represent the average ± SD of four independent experiments in two EGFP++ iPSC
lines. *p < 0.0001, **p < 0.000001.shorter G0/G1 phase that is characteristic of hPSCs,
compared with somatic cell types such as fibroblasts.
While this manuscript was in preparation, Gutschner
et al. (2016) also described a version of SpCas9 fused to
the N-terminal region of human Geminin. Although the
authors reported a modest increase (28%–87%) in HR
compared with unmodified SpCas9 in HEK293T cells, their
Cas9-Geminin fusion provoked similar levels of indel for-
mation. This may be explained by their use of plasmid
DNA to express Cas9 from a b-actin promoter, resulting
in sustained levels of nuclease transcription that likely per-
sists over several days and during the course of multiple cy-
cles of cell division. In the study presented here, transfec-
tion of in vitro transcribed mRNA was utilized, enabling514 Stem Cell Reports j Vol. 7 j 508–517 j September 13, 2016uniform and transient expression of SpCas9-Gem protein
during S/G2. Following degradation during G1, nuclease
levels are drastically reduced, even in subsequent S/G2
phases, which canmost likely be attributed to the transient
and unstable properties of mRNA.
Of note, the SpCas9-Cdt1 variant also enabled the gener-
ation of correctly targeted lines, albeit with a lower effi-
ciency than the unmodified or SpCas9-Gem variants.
Although this may be due to the fact that proteins fused
to the Cdt1 peptide can persist during the initial stages of
S phase, when HR becomes a potential option for DNA
repair, this may also be the result of incomplete degrada-
tion of SpCas9-Cdt1 during S/G2/M (see Figure 1). The
SpCas9-Cdt1 fusion induced indel formation significantly
more often than SpCas9-Gem but at a lower frequency
than unmodified SpCas9, which was particularly evident
when assessing the total number of alleles disrupted by
NHEJ. It is difficult to determine whether this is due to
lower overall levels of SpCas9-Cdt1 or perhaps a reduced
nuclease activity relative to unmodified SpCas9.
Although any off-target effects associated with the Cas9
variants generated in this study were not analyzed, the
lower NHEJ activity of SpCas9-Gem would likely translate
to a reduction in unwanted mutations across the genome.
Nonetheless, the incorporation of the Geminin peptide
into the recently described high-fidelity versions of SpCas9
(SpCas9-HF1 and eCas9) (Kleinstiver et al., 2016; Slaymaker
et al., 2016) may reduce the likelihood of off-target NHEJ
further.
In conclusion, the SpCas9-Gemvariant described here fa-
cilitates efficient and reliable generation of knockin and
gene-corrected hPSC lines free of unwanted mutations at
the targeted locus. Our results demonstrate the utility of
SpCas9-Gem for achieving effective and precise genome
modifications while minimizing the ‘‘on-target’’ effects of
NHEJ in both somatic cells types, such as fibroblasts, and
pluripotent cell types, such as embryonic stem cells and
iPSCs. This is a significant advance in the downstream
application of hPSCs for disease modeling and functional
genomics, and prepares the field for gene-correction appli-
cations in regenerative medicine. The use of additional
peptides or sequences that promote greater cell-cycle spec-
ificity of Cas9 may permit even further reductions in ‘‘on-
target’’ NHEJ while increasing desirable HR activity.EXPERIMENTAL PROCEDURES
Oligonucleotide and gBlock Sequences
A list of oligonucleotide (ODN) sequences for PCR amplification
and generation of sgRNA plasmids (Table S4) and complete se-
quences of the gBlocks (Integrated DNA Technologies) used in
this study can be found in Supplemental Sequencing Data.
Vector Construction
To enable in vitro transcription of mRNA encoding SpCas9, an
XbaI-NsiI fragment from plasmid hCas9 (Addgene plasmid
#41815) containing the entire SpCas9 sequence was inserted into
the NheI and SbfI sites of the pDNR-Dual vector (Clontech), to
generate pDNR-SpCas9. The SpCas9-Gem variant was generated
by PCR-amplifying sequence from hCas9 using ODNs 1 and 2
and sequence from pTRE-CellCycle (Clontech) using ODNs 3
and 4 followed by insertion into the EcoRI and AgeI restriction sites
in pDNR-SpCas9. The pSpCas9-CdtI variantwas generated by PCR-
amplifying sequence from hCas9 using ODNs 1 and 2 and
sequence frompTRE-CellCycle (Clontech) usingODNs 3 and 5 fol-
lowed by insertion into the EcoRI and AgeI restriction sites in
pDNR-SpCas9. For construction of the DNMT3B targeting vector,
a gBlock encoding 50 BglII and NdeI sites, nucleotides 150–724 ofthe EGFP gene, an SV40 polyA signal, and 700 bp of sequence
beginning at the DNMT3B start codon was cloned into the HincII
site of the pSMARTHCKan plasmid vector (Lucigen). ODNs 6 and
7 were used to PCR amplify (from a previously generated BAC
clone carrying an EGFP reporter inserted at the DNMT3B
start codon) a DNA fragment carrying an approximately 1.1-kb
sequence upstream of the DNMT3B start codon and the first
150 bp of EGFP, which was subsequently inserted into the BglII
and NdeI sites of the plasmid described above. A plasmid designed
for insertion and expression of sgRNA sequences was constructed
by inserting a gBlock encoding a U6 promoter, two BbsI sites,
and SpCas9-specific tracrRNA sequence into the HincII site of
pSMARTHCKan. ODNs specific to each target locus were annealed
and inserted into the BbsI sites of the pSMART-sgRNA vector. For
repair of the patient-specific mutation, two gBlocks encoding a to-
tal of 1750 bp of the SCN2A gene was inserted into the AatII and
EcoRI sites of the pDNR-Dual vector. A serine residue within the re-
gion recognized by our SCN2A-specific sgRNA was changed from
TCA to AGT to minimize Cas9-induced cutting of the plasmid
following its introduction into cells. A BFP targeting vector was
generated by inserting a gBlock encoding the full-length BFP
gene into the AatII and EcoRI sites of pDNR-Dual. The DNMT3B
gene-targeting construct containing the EGFP and puromycin
resistance genes was generated as previously described (Howden
et al., 2015). The plasmids used for in vitro transcription of native
SpCas9 (plasmid 80425), SpCas9-Gem (plasmid 80424), and
SpCas9-Cdt1 (plasmid 80426) along with the plasmid used for
sgRNA expression (plasmid 80427) are all available from Addgene
upon request.In Vitro Transcription
Capped and polyadenylated in vitro transcribed mRNA encoding
SpCas9, SpCas9-Gem, and SpCas9-Cdt1 was generated using the
mMESSAGE mMACHINE T7 ULTRA transcription kit (Thermo
Fisher) according to the manufacturer’s recommendations.
Plasmid template was linearized with PmeI prior to transcription.
LiCl was used to precipitate mRNA before resuspension. A trun-
cated version of the EBNA1 protein was transcribed using the
mMESSAGE mMACHINE SP6 transcription kit, as previously
described (Howden et al., 2006).Transfection
All transfections were performed using the Neon Transfection Sys-
tem (Thermo Fisher). For simultaneous reprogramming and gene
editing of human fibroblasts, cells were harvested with TrypLE
(Thermo Fisher) 2 days after passaging and resuspended in Buffer
R at a final concentration of 13 107 cells/mL. One hundredmicro-
liters of the cell suspension was added to a tube containing plas-
mids necessary for both reprogramming and gene targeting as
well as mRNA encoding either SpCas9, SpCas9-Gem, or SpCas9-
Cdt1. In vitro transcribed mRNA encoding a truncated version of
the EBNA1 protein was also included to enhance nuclear uptake
of the reprogramming plasmids (Chen et al., 2011; Howden
et al., 2006). See Table S5 for DNA/mRNA concentrations used in
each transfection. Electroporation was performed in 100- mL tips
using the following conditions: 1,400 V, 20 ms, two pulses.
Following electroporation, cells were plated on a single 10-cmStem Cell Reports j Vol. 7 j 508–517 j September 13, 2016 515
Matrigel-coated (Corning) plate and maintained in fibroblast me-
dium until 4 days post transfection, then switched to E7 medium
(E8 mediumwithout transforming growth factor b) supplemented
with 100 mM sodium butyrate and changed every other day as
described previously (Chen et al., 2011). Sodium butyrate was
removed from the medium after the appearance of the first iPSC
colonies at around day 10. iPSC and H9 transfections were per-
formed in 10- mL and 100- mL tips, respectively, according to the
manufacturer’s recommendation using the following conditions:
1,100 V, 30 ms, one pulse. Following transfection, cells were trans-
ferred to Matrigel-coated plates containing E8 medium supple-
mented with 5 mM Y-27632 (Tocris), which was omitted in subse-
quent media changes.
Cell Culture
Fibroblast lines were derived from donors with informed parental
consent and approval from the local research ethics committee. Fi-
broblasts were cultured in DMEM (Thermo Fisher) supplemented
with 15% fetal bovine serum (HyClone) at 37C, 5% CO2, and
5% O2. All hPSC lines were maintained and expanded in E8 me-
dium with daily media changes and passaged every 3–4 days
with EDTA in 13 PBS as previously described (Chen et al., 2011).
PCR, RT-PCR, and Sanger Sequencing
Total genomic DNAwas extracted using the DNeasy Blood and Tis-
sue kit (Qiagen). PCR was performed using GoTaq Green PCRMas-
termix (Promega). Sequence encompassing the DNMT3B start
codon and surrounding region PCR was amplified using ODNs 8
and 9. Exon 14 of SCN2A and surrounding sequence was amplified
using ODNs 15 and 16. Prior to sequencing, PCR amplicons
were treated with rAPid Alkaline Phosphatase (Roche Life Science)
and Endonuclease I (NEB) for 30 min at 37C followed by heat
inactivation at 80C for 15 min. Sequencing reactions were per-
formed using BigDye Terminator v3.1 (Thermo Fisher). Reactions
were purified and sequenced by the Australian Genome Research
Facility.
Flow Cytometry
Cells were analyzed for EGFP and BFP expression by flow cytome-
try using a LSRFortessa Call Analyzer (BD Biosciences). Data acqui-
sition and analysis were performed using FACSDiva (Becton Dick-
inson) and FlowLogic software (Inivai). Gating was performed on
live cells based on forward and side scatter analysis.
Cell Sorting
Prior to sorting, cells were harvested with TrypLE and resuspended
in 2 mL of E8 medium containing Hoechst 33,342 (10 mg/mL) and
incubated at 37C for 30 min. Cells were sorted according to their
DNA content using a FACSAria FusionCell Sorter (BD Biosciences).
Western Blot
Western blots were performed by standard Tris-glycine SDS-PAGE
followed by transfer to polyvinylidene fluoride membranes.
Following blocking with 10% skim milk in TBS-T (20 mM Tris-Cl
[pH 8.0], 150 mMNaCl, 0.1% Tween 20), membranes were probed
with anti-CRISPR/Cas9 (Abcam, ab191468) at 1 mg/mL and anti-516 Stem Cell Reports j Vol. 7 j 508–517 j September 13, 2016b-actin (Cell Signaling Technology, #4970) at 1:5,000 and visual-
ized by chemiluminescence.
Intracellular Staining
Prior toharvest, cellswere incubated inmediumcontainingHoechst
33342 (10 mg/mL) at 37C for 30 min. Cells were harvested,
fixed with 2% paraformaldehyde, and permeabilized with 0.1%
Triton X-100. Cells were stained with anti-CRISPR/Cas9 (AbCam,
ab191468) for1hr followedbystainingwithagoat immunoglobulin
G anti-mouse secondary antibody directly conjugated to allophyco-
cyanin. Cells were analyzed by flow cytometry as described above.
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